QIAGEN Proposes Expansion of Supervisory Board
- Dr. Eva Pisa proposed as a new member to the Supervisory Board, contributes significant leadership experience in Life Science and Molecular Diagnostics industry
- All seven current Supervisory Board members to stand for re-election for one-year terms
- Annual General Meeting to be held on June 23, 2022, in Venlo, the Netherlands
VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the proposal of Dr. Eva Pisa, a leader in health diagnostics and biotechnology who has extensive experience from start-ups to corporate companies, as a new member of the Supervisory Board.
Dr. Pisa, along with all seven current members of the Supervisory Board, will be proposed for election to one-year terms at the next Annual General Meeting, which is scheduled for June 23, 2022, and to be held in person in Venlo, the Netherlands.
The current Supervisory Board members are Lawrence A. Rosen (Chair), Dr. Metin Colpan, Thomas Ebeling, Dr. Toralf Haag, Prof. Dr. Ross Levine, Prof. Dr. Elaine Mardis and Elizabeth A. Tallett. Thierry Bernard (Chief Executive Officer) and Roland Sackers (Chief Financial Officer) are also proposed for re-election as the Managing Board members for one-year terms.
“After two years of virtual meetings due to the COVID-19 pandemic, we welcome this opportunity to again meet in person with our shareholders,” said Lawrence A. Rosen, Chair of the Supervisory Board of QIAGEN N.V. “On behalf of my colleagues in the Supervisory Board and Managing Board, we are delighted to welcome Dr. Eva Pisa to our Supervisory Board. She brings proven leadership insights and extensive industry experience to QIAGEN that will deeply enrich the capabilities in our Board in terms of science and business acumen. As shown through our performance for 2021, and the outlook for 2022, QIAGEN is moving ahead with the right strategy and focus on execution to create value in the Life Science and Molecular Diagnostics markets for our stakeholders, including our shareholders.”
Dr. Pisa was the CEO of Sangtec Molecular Diagnostics AB, a Swedish molecular diagnostic start-up, from 2001-2007 that was acquired by Cepheid (now part of Danaher) and specialized in infectious diseases affecting immune-compromised patients. She then worked for Roche Diagnostics International from 2007-2020, where she held positions of increasing responsibility. During her tenure, the Roche cobas 6800 / 8800 System was developed and launched. Dr. Pisa most recently served as Senior Vice President at Roche Centralized and POC Solutions, where she was responsible for Clinical Chemistry, Endocrinology and Custom Biotech (B2B business). She continues to support and consult with diagnostic and life science companies. Dr. Pisa holds a Ph.D. from the Karolinska Institute in Sweden and an MBA from Heriot-Watt University in Scotland.
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of March 31, 2022, QIAGEN employed more than 6,000 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).
Source: QIAGEN N.V.
John Gilardi +49 2103 29 11711
Phoebe Loh +49 2103 29 11457
Thomas Theuringer +49 2103 29 11826